Moreover, the combination of PI3K inhibitors with CAR-T therapy is based on the rationale that CAR-T cells in vivo might become rapidly exhausted upon encounter with target-antigen on tumor cells and subsequent CD28 downstream signaling. Here, CD28 is linked to neoplasm.